Dr Coulter’s research is focused on novel targeted nanomedicines designed to work in synergy with existing cancer therapeutics.

His research has developed nanoparticle formulations exploiting tumour inflammation and the tumour microenvironment (low oxygen). Targeting disease characteristics enhances nanomedicine specificity while limiting off-target effects.   

Recent collaborations (industrial and academic) are focused on sustained release platforms, allowing exploitation of nano-formulations to deliver patient benefit. Coulter’s research is currently focused on prostate and head and neck cancer, as radiotherapy represents a key treatment option.